{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:02:46Z","timestamp":1792785766252,"version":"4.5.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Lung Cancer Research from the Japan Lung Cancer Society","id":[{"id":"https:\/\/ror.org\/035gxp094","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Optimal corticosteroid treatment duration for immune checkpoint inhibitor (ICI)\u2013related pneumonitis remains uncertain. No randomized trials have addressed this issue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine whether a 3-week corticosteroid taper is noninferior to the guideline-recommended 6-week taper for short-term treatment success in patients with mild (Common Terminology Criteria for Adverse Events grade 1-2) immune-related pneumonitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with mild immune-related pneumonitis were assigned to either a 3-week or 6-week corticosteroid regimen. The primary endpoint was the treatment success rate at 8\u2009weeks, defined as resting room-air SpO2\u2009\u2265\u200990% without steroid escalation or prolongation due to pneumonitis worsening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and main results<\/jats:title>\n                    <jats:p>Overall, 106 patients were randomly assigned (median age = 72\u2009years; grade 2, 73%). Treatment success rates were 66.7% and 85.2% in the 3- and 6-week groups, respectively, which did not demonstrate noninferiority (difference = \u221218.5 percentage points; 80% CI, \u221229.0% to \u22127.9%; P\u2009=\u2009.621) of the 3-week regimen. A predefined exploratory analysis indicated superiority of the 6-week regimen (P\u2009=\u2009.013). Grade\u2009\u22653 adverse events occurred in 12% and 24% of the 3- and 6-week groups, respectively; however, all were manageable with clinical interventions. The total quality of life mean change using the King\u2019s Brief Interstitial Lung Disease score from baseline was 4.78 and 6.28 in the 3- and 6-week groups, respectively (between-group difference = \u22121.50 percentage points; 95% confidence interval, \u22125.91 to 2.91). Overall survival was comparable between the groups (hazard ratio = 1.03; 95% CI, 0.46-2.29; P\u2009=\u2009.95).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study establishes the 6-week corticosteroid regimen as an evidence-based standard for treating ICI-related pneumonitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajrccm\/aamag349","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:37:54Z","timestamp":1782992274000},"page":"2482-2492","source":"Crossref","is-referenced-by-count":1,"title":["Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial"],"prefix":"10.1093","volume":"212","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0615-3000","authenticated-orcid":false,"given":"Daichi","family":"Fujimoto","sequence":"first","affiliation":[{"name":"Internal Medicine III, Wakayama Medical University , Wakayama,","place":["Japan"]},{"name":"Department of Respiratory Medicine, Hyogo Medical University , Nishinomiya,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Respirology, Graduate School of Medicine, Chiba University , Chiba,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0623-9365","authenticated-orcid":false,"given":"Kenta","family":"Murotani","sequence":"additional","affiliation":[{"name":"School of Medical Technology, Kurume University , Kurume,","place":["Japan"]},{"name":"Biostatistics Center, Kurume University , Kurume,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihoko Imaji","family":"Onishi","sequence":"additional","affiliation":[{"name":"Internal Medicine III, Wakayama Medical University , Wakayama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kobe City Medical Center General Hospital , Kobe,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisaku","family":"Miyauchi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tohoku University Graduate School of Medicine , Sendai,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Takase","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NHO Minami Wakayama Medical Center , Tanabe,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine , Aomori,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kijima","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hyogo Medical University , Nishinomiya,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, NHO Kinki Chuo Chest Medical Center , Sakai,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9093-3442","authenticated-orcid":false,"given":"Ayumu","family":"Otsuki","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Kameda Medical Center , Kamogawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Sugisaka","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Sendai Kousei Hospital , Miyagi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yokouchi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NHO Hokkaido Cancer Center , Sapporo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Arai","sequence":"additional","affiliation":[{"name":"Pulmonary Division, Department Internal Medicine, Saiseikai Utsunomiya Hospital , Utsunomiya, Tochigi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Sakata","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Saiseikai Kumamoto Hospital , Kumamoto,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Tamiya","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Osaka International Cancer Institute , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Niigata Cancer Center Hospital , Niigata,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Osaka Habikino Medical Center , Habikino,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center , Amagasaki,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon H","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Osaka Hospital , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8909-5709","authenticated-orcid":false,"given":"Teppei","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Aichi Cancer Center Hospital , Nagoya, Aichi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuka","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Saiseikai Suita Hospital , Suita, Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medicine and Dental Sciences , Niigata,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Shibaki","sequence":"additional","affiliation":[{"name":"Internal Medicine III, Wakayama Medical University , Wakayama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Kikawa","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Kansai Medical University Hospital , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Tomii","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kobe City Medical Center General Hospital , Kobe,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Sumikawa","sequence":"additional","affiliation":[{"name":"Department of Radiology, NHO Kinki Chuo Chest Medical Center , Sakai,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Internal Medicine III, Wakayama Medical University , Wakayama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Akamatsu","sequence":"additional","affiliation":[{"name":"Internal Medicine III, Wakayama Medical University , Wakayama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"2026093006123195400_aamag349-B1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"2026093006123195400_aamag349-B2","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"2026093006123195400_aamag349-B3","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"2026093006123195400_aamag349-B4","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.4110\/in.2022.22.e2","article-title":"Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy","volume":"22","author":"Lee","year":"2022","journal-title":"Immune Netw"},{"key":"2026093006123195400_aamag349-B5","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026093006123195400_aamag349-B6","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"2026093006123195400_aamag349-B7","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.chest.2021.02.032","article-title":"Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina","volume":"160","author":"Atchley","year":"2021","journal-title":"Chest"},{"key":"2026093006123195400_aamag349-B8","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2026093006123195400_aamag349-B9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026093006123195400_aamag349-B10","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"2026093006123195400_aamag349-B11","doi-asserted-by":"publisher","first-page":"100265","DOI":"10.1016\/j.jtocrr.2021.100265","article-title":"A real-world study on the effectiveness and safety of pembrolizumab plus chemotherapy for nonsquamous NSCLC","volume":"3","author":"Fujimoto","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"2026093006123195400_aamag349-B12","doi-asserted-by":"publisher","first-page":"e004670","DOI":"10.1136\/jitc-2022-004670","article-title":"Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study","volume":"10","author":"Tiu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026093006123195400_aamag349-B13","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026093006123195400_aamag349-B14","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1038\/s41598-023-30676-y","article-title":"Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer","volume":"13","author":"Fujimoto","year":"2023","journal-title":"Sci Rep"},{"key":"2026093006123195400_aamag349-B15","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"2026093006123195400_aamag349-B16","doi-asserted-by":"publisher","first-page":"j1415","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"key":"2026093006123195400_aamag349-B17","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026093006123195400_aamag349-B18","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.3390\/cancers15113041","article-title":"Better late than never: the impact of steroidal treatment on the outcome of melanoma patients treated with immunotherapy","volume":"15","author":"Bar-Hai","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026093006123195400_aamag349-B19","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.1158\/1078-0432.CCR-21-1283","article-title":"Early use of high-dose glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy","volume":"27","author":"Bai","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026093006123195400_aamag349-B20","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s00262-024-03772-9","article-title":"Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependent","volume":"73","author":"Albarr\u00e1n","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"2026093006123195400_aamag349-B21","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.chest.2020.11.027","article-title":"Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the Fleischner Society","volume":"159","author":"Johkoh","year":"2021","journal-title":"Chest"},{"key":"2026093006123195400_aamag349-B22","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1136\/thoraxjnl-2012-201581","article-title":"The development and validation of the King\u2019s Brief Interstitial Lung Disease (K-BILD) health status questionnaire","volume":"67","author":"Patel","year":"2012","journal-title":"Thorax"},{"key":"2026093006123195400_aamag349-B23","doi-asserted-by":"publisher","first-page":"1900281","DOI":"10.1183\/13993003.00281-2019","article-title":"King\u2019s Brief Interstitial Lung Disease questionnaire: responsiveness and minimum clinically important difference","volume":"54","author":"Nolan","year":"2019","journal-title":"Eur Respir J"},{"key":"2026093006123195400_aamag349-B24","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"2026093006123195400_aamag349-B25","doi-asserted-by":"publisher","first-page":"e000363","DOI":"10.1136\/bmjresp-2018-000363","article-title":"The King\u2019s Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference","volume":"6","author":"Sinha","year":"2019","journal-title":"BMJ Open Respir Res"},{"key":"2026093006123195400_aamag349-B26","doi-asserted-by":"publisher","first-page":"e001731","DOI":"10.1136\/jitc-2020-001731","article-title":"Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes","volume":"9","author":"Balaji","year":"2021","journal-title":"J Immunother Cancer"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/advance-article-pdf\/doi\/10.1093\/ajrccm\/aamag349\/68694008\/aamag349.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/212\/10\/2482\/68694008\/aamag349.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/212\/10\/2482\/68694008\/aamag349.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:12:39Z","timestamp":1790763159000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/212\/10\/2482\/8724499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,7,3]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajrccm\/aamag349","relation":{},"ISSN":["1535-4970"],"issn-type":[{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,7,3]]}}}